Aytu Biopharma (AYTU) Cost of Revenue (2014 - 2026)
Aytu Biopharma (AYTU) posted quarterly Cost of Revenue of $4.8 million for Q1 2026, down 14.77% year-over-year from $5.6 million in Q1 2025, and down 13.16% quarter-over-quarter from $5.5 million in Q4 2025.
Aytu Biopharma (AYTU) Cost of Revenue (2014 - 2026) Analysis & Trends
Aytu Biopharma (AYTU) has reported Cost of Revenue for 13 consecutive years, with $4.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cost of Revenue fell 14.77% year-over-year to $4.8 million; the TTM figure through Mar 2026 stood at $19.9 million (up 3.77% YoY), while the FY2025 annual figure was $20.6 million, up 27.42% from the prior year.
- Cost of Revenue fell to $4.8 million in Q1 2026 per AYTU's latest filing, from $5.5 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $12.6 million in Q2 2022 and bottomed at $3.5 million in Q2 2024.
- Historically, Cost of Revenue has averaged $6.9 million across 5 years, with a median of $5.4 million in 2024.
- Annual changes were most pronounced in 2024 — Cost of Revenue plunged 70.9% — and 2025, when it surged 54.09%.
- Aytu Biopharma's Cost of Revenue stood at $9.0 million in 2022, then plunged by 53.87% to $4.1 million in 2023, then soared by 31.12% to $5.4 million in 2024, then advanced by 1.95% to $5.5 million in 2025, then decreased by 13.16% to $4.8 million in 2026.
- Business Quant data shows AYTU's Cost of Revenue at $4.8 million in Q1 2026, $5.5 million in Q4 2025, and $4.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Aytu Biopharma | 24.86 Mn | -1.86 Mn | 7.60 Mn | 4.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.81 Mn |
| Mar 31, 2026 | 4.81 Mn |
| Dec 31, 2025 | 5.54 Mn |
| Dec 31, 2025 | 5.54 Mn |
| Sep 30, 2025 | 4.70 Mn |
| Sep 30, 2025 | 4.70 Mn |
| Jun 30, 2025 | 4.88 Mn |
| Jun 30, 2025 | 4.88 Mn |
| Mar 31, 2025 | 5.65 Mn |
| Mar 31, 2025 | 5.65 Mn |
| Dec 31, 2024 | 5.44 Mn |
| Dec 31, 2024 | 5.44 Mn |
| Sep 30, 2024 | 4.59 Mn |
| Sep 30, 2024 | 4.59 Mn |
| Jun 30, 2024 | 3.54 Mn |
| Jun 30, 2024 | 3.54 Mn |
| Mar 31, 2024 | 3.66 Mn |
| Mar 31, 2024 | 3.66 Mn |
| Dec 31, 2023 | 4.15 Mn |
| Dec 31, 2023 | 4.15 Mn |